Date: 2017-12-06
Type of information: Milestone
Compound: drugs for a new undisclosed target
Company: Servier (France) Vernalis (UK)
Therapeutic area: Cancer - Oncology
Type agreement: R&D - research
Action mechanism:
Disease:
Details:
- • On January 17, 2012, Vernalis and Servier announced that they have entered into a new three-year joint oncology collaboration focused on the discovery of drugs for a new undisclosed target. The collaboration will utilise Vernalis’ proprietary fragment and structure-based drug discovery platform.This is the third collaboration between Vernalis and Servier on undisclosed oncology targets.
Financial terms:
- Vernalis will receive fees and a share in the future success of the product in the form of milestones and royalties on sales.Financial terms of the collaboration are not disclosed.
Latest news:
- • On December 6, 2017, Vernalis and Servier announced the achievement of a pre-clinical milestone in their third oncology drug discovery collaboration. Vernalis will receive a payment of €1.0m from Servier in recognition of this achievement. This collaboration with Servier was initiated in January 2012 and utilises Vernalis’ proprietary fragment- and structure-based drug discovery platform. Vernalis receives fees and a share in the future success of the product in the form of milestones and royalties on sales. Financial terms are not disclosed.
- • On July 19, 2016, Vernalis and Servier have announced the achievement of a new milestone in their first oncology drug discovery collaboration, triggering a payment of €500K to Vernalis. Vernalis and Servier have been working in partnership using Vernalis’ proprietary fragment and structure-based drug discovery platform on a number of oncology targets, including Bcl-2 and Mcl-1. This milestone relates to success against an undisclosed target.
- • On August 4, 2014, Vernalis and Servier announced the achievement of two milestones in their oncology drug discovery collaborations, triggering a payment of €0.75m to Vernalis. Vernalis and Servier have been working in partnership since initiating their first collaboration in May 2007. The collaborations utilise Vernalis’ proprietary fragment and structure-based drug discovery platform on a number of oncology targets, of which only Bcl-2 is disclosed. Under the collaborations Vernalis receives fees and a share in the future success of any products in the form of development milestones and royalties on sales. Financial terms are not disclosed.
Is general: Yes